Intensification of Gla-100 with Prandial Insulin: A Stepwise Progression Toward Glycemic Control.


Journal

The Journal of the Association of Physicians of India
ISSN: 0004-5772
Titre abrégé: J Assoc Physicians India
Pays: India
ID NLM: 7505585

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 28 11 2020
pubmed: 29 11 2020
medline: 2 12 2020
Statut: ppublish

Résumé

The inadequate control of postprandial glucose (PPG) excursions, are linked in some studies with cardiovascular disease. Even though basal insulins, such as insulin glargine 100 U/mL (Gla-100), maintain overall glycemic control, effective PPG control eventually requires intensification of therapy by adding prandial insulins. Compared to conventional basal-bolus or premixed approaches, a stepwise basal-plus or basal-prandial intensification regimen involving the addition of one, two, or three prandial insulins to basal therapy such as Gla-100, has received much attention in recent times. This intensification approach is comparable to other conventional approaches in terms of glycemic control, and offers the additional advantages of fewer hypoglycemic events, personalization of therapy, and a simple self-management algorithm for titration. Owing to such benefits, recent guidelines recommend its use over other approaches for initiating intensification. It is preferred by both physicians and patients and is a better alternative to immediately embarking on a full basal-bolus regimen or introducing premixed insulin preparations for intensification of therapy.

Identifiants

pubmed: 33247663

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0
Hypoglycemic Agents 0
Insulin 0
Insulins 0
Insulin Glargine 2ZM8CX04RZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-48

Informations de copyright

© Journal of the Association of Physicians of India 2011.

Auteurs

Subhash Kumar Wangnoo (SK)

Senior Consultant Endocrinologist, Apollo Centre for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospitals, New Delhi.

Suresh Damodharan (S)

Senior Consultant, Sri Ramakrishna Hospital, Coimbatore, Tamil Nadu.

N G Sastry (NG)

Director and Senior Consultant, Dr. Mohan's Diabetes Specialities Center, Hyderabad, Telangana.

Supratik Bhattacharyya (S)

Consultant, Apollo clinic, Newtown, Kolkata, West Bengal.

Chitra Selvan (C)

Consultant Endocrinologist, Department of Endocrinology, MS Ramaiah Memorial Hospital, Bangalore, Karnataka.

Brij Mohan (B)

Senior Consultant Physician, BMC Hospital, Kanpur, Uttar Pradesh.

Chandan Sarmah (C)

Consultant, Maa Gayatri Medical Clinic, Tinsukia, Assam.

Avinash Arivazhahan (A)

Medical Affairs, Diabetes and Cardiovascular, Sanofi India Ltd., Mumbai, Maharashtra.

Viswanathan Mohan (V)

Chairman and Chief Diabetologist, Dr. Mohan's Diabetes Specialities Centre, Chennai, Tamil Nadu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH